CurrentCapital BluecrossPolicy MP 9.001

Placental/umbilical cord blood as a source of stem cells

This policy defines medical necessity and investigational uses for transplantation, collection, and storage of placental/umbilical cord blood stem cells for Capital BlueCross members and applies to applicable products/programs.

Policy Summary

PayerCapital Bluecross

PolicyPlacental/umbilical cord blood as a source of stem cells

Policy CodePolicy MP 9.001

Change TypeAdministrative update — no material clinical changes

Effective DateDec 1, 2025

Next Review Date

Key ActionObtain prior authorization when billing the listed cord blood procedure codes (S2140, S2142, S2150).

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

CoveredAllogeneic transplant covered

InvestigationalProphylactic storage stance

3Procedure codes listed

12/1/2025Effective date

Coverage Criteria — Placental / Umbilical Cord Blood

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

inv-01: Allogeneic cord blood transplantation — Covered when ALL of the following are met

Covered when ALL of the following are met

Allogeneic transplant indication: Transplantation of cord blood stem cells from related or unrelated donors may be considered medically necessary in patients with an appropriate indication for allogeneic stem-cell transplant.

See specific HCT policies for condition-specific selection criteria.

inv-02: Collection and storage when allogeneic transplant imminent — single top-level node

Collection when transplant imminent: Collection and storage of cord blood from a neonate may be considered medically necessary when an allogeneic transplant is imminent in an identified recipient with a diagnosis that is consistent with the possible need for allogeneic transplant.

inv-03: Prophylactic collection and storage — coverage stance for prophylactic storage

Prophylactic collection/storage: Prophylactic collection and storage of cord blood from a neonate is considered investigational when proposed for unspecified future autologous use by the donor or for unspecified future allogeneic use in a related or unrelated recipient.

No evidence identified demonstrating benefit of prophylactic autologous cord blood use for malignant neoplasms.

Transplantation of cord blood stem cells is considered medically necessary only when used as an allogeneic stem-cell transplant for patients with an appropriate indication. In all other clinical situations, cord blood transplantation is considered investigational due to insufficient evidence of benefit.

Policy history documents an administrative update on 10/22/2024 that reclassified “Prophylactic collection and storage of cord blood from a neonate for unspecified future use” from Not Medically Necessary to Investigational; subsequent entries note administrative and reference updates through 10/29/2025.

Prophylactic collection and storage of cord blood from a neonate for an unspecified future use — either as autologous use by the donor or for an unspecified future allogeneic recipient — is considered investigational because there is insufficient evidence demonstrating safety or effectiveness for those indications.

Earlier versions of this policy classified prophylactic collection and storage of cord blood for unspecified future use as Not Medically Necessary; the policy history shows this was changed to Investigational on 10/22/2024, with additional administrative updates recorded through 2025.

Provider Actions, Authorization, and Documentation

Prior Authorization

Prior Authorization (check member benefit)

Prior authorization requirements are not explicitly specified in the provided policy text. Providers should verify prior authorization requirements with the member's specific benefit plan before scheduling services, as coverage and administrative requirements depend on the member's benefit information.

Prior authorization: Not specified in policy text — check member benefit and plan-specific prior authorization rules before billing.

Denial Risk

Prophylactic Storage — Investigational

Prophylactic collection and storage of cord blood from a neonate for unspecified future use (autologous or allogeneic) is considered investigational per the policy and should be treated as such for coverage determination.

Policy statement: "Prophylactic collection and storage of cord blood ... may be considered investigational when proposed for some unspecified future use."
Coding/history note: Policy updated 10/22/2024 to change this use from NMN to investigational (INV).

Documentation Required

Regulatory/Documentation Requirements for Cord Blood Facilities

Facilities that prepare cord blood for potential use by patients unrelated to the donor must comply with FDA regulatory requirements; facilities preparing only for autologous and/or first- or second-degree relatives must register and follow Good Tissue Practices and donor suitability processes.

Unrelated-donor cord blood: product must be licensed under a biologics license application or an investigational new drug (IND) application prior to use.
Related/autologous-only programs: facility registration and listing, adherence to FDA Good Tissue Practices, and applicable donor suitability determination processes are required.

Note

Payer Communication Scope

Capital Blue Cross issues communications in its role as administrator for programs it issues or administers. Providers should follow administrator communications for program-specific instructions and provider relations matters.

Scope: Communications apply to programs issued or administered by Capital Blue Cross and its subsidiaries; independent licensees of the Blue Cross BlueShield Association.
Action: Follow administrator communications for program-specific guidance, benefit variations, and provider relations.

Note

Administrative Updates Noted

Administrative updates and policy history items that may affect interpretation or administrative processing are noted in the policy history; providers should review the policy history for recent administrative changes.

10/22/2024: Updated policy language to classify prophylactic collection/storage for unspecified future use as investigational; references updated; coding reviewed.
01/15/2025: Administrative update removed NCCN statement.
10/29/2025: Administrative update removed Benefit Variations Section and updated Disclaimer.
Other: Multiple consensus reviews with no change to policy statements; coding reviews noted.

Evaluation and Clinical Context Requirements

Documentation Required

HLA typing/compatibility required for donor evaluation

HLA typing and compatibility evaluation are required as part of donor selection for allogeneic transplantation.

Perform HLA compatibility testing when evaluating donors for allogeneic cord blood transplant

Note

Clinical studies cited for umbilical cord blood transplant comparisons

Multiple comparative studies of UCBT versus other graft sources are cited and provide clinical context for graft selection and outcomes.

Meta-analyses and comparative studies of UCBT vs bone marrow, haploidentical, and double-unit grafts are referenced

Center and Facility Requirements

Documentation Required

Center must have FDA licensure or IND for unrelated recipients

Facilities preparing cord blood for unrelated recipients must have FDA licensure or investigational approvals and adhere to applicable regulations and standards.

Unrelated-recipient use requires biologics licensure or IND prior to use

Documentation Required

Center requirements for autologous/related-only cord blood preparation

Centers must register and follow FDA Good Tissue Practices when preparing cord blood units for autologous or related recipients and adhere to donor suitability processes.

Autologous/related-only preparations: registration, product listing, and adherence to Good Tissue Practices

Documentation Required

Accreditation standards (NetCord-FACT) referenced for centers

Refer to NetCord-FACT international standards and accreditation as relevant guidance for cord blood collection, banking, and release procedures.

NetCord-FACT accreditation standards are cited in policy references

Note

NetCord-FACT standards cited for facility practices

NetCord-FACT international standards are included in the references, implying accreditation and adherence to those standards are relevant to center practices.

Definitions

Allogeneic

DefinitionHaving a different genetic constitution involving a donor and a recipient (allogeneic).

ContextIn allogeneic hematopoietic stem-cell transplantation, immunologic compatibility between donor and recipient is critical and is established by HLA typing (HLA-A, -B, -DR).

Source cellsAllogeneic stem cells may be obtained from related or unrelated donors and harvested from bone marrow, peripheral blood, or umbilical cord blood shortly after delivery.

Autologous

DefinitionOriginating within an individual (autologous); self-donation of hematopoietic stem cells.

Clinical noteAutologous HCT uses the patient’s own stem cells and does not require immunologic compatibility testing.

Typical useOften performed as consolidation therapy when the patient's disease is in complete remission to permit high-dose cytotoxic therapy and subsequent engraftment.

Cord blood

DefinitionBlood from the umbilical cord that connects the circulatory system of the fetus to the placenta (cord blood).

ContentsCord blood contains hematopoietic stem/progenitor cells that can be used as a source for transplantation.

Regulatory referenceCord blood banking and transplantation are addressed in FDA guidance and international standards (see references).

Umbilical cord blood transplantation (UCBT)

DefinitionTransplantation of hematopoietic stem/progenitor cells derived from placental/umbilical cord blood used to reconstitute hematopoiesis (UCBT).

Clinical comparisonsMultiple studies compare UCBT outcomes with bone marrow, unrelated donor transplants, haploidentical transplants, and double-unit grafts to inform graft selection and outcomes.

Historical noteUCBT has been used successfully in pediatric and adult patients and is described in foundational and comparative studies (see references).

Post-Transplant Coverage Considerations

Immunosuppressive therapy and posttransplant care — coverage subject to member benefits and medical necessity

Coverage rulePosttransplant immunosuppressant management is standard; coverage for immunosuppressive therapy and posttransplant care is subject to member benefits and medical necessity.

Purpose of therapyImmunosuppressants are required after allogeneic HCT to minimize graft rejection and graft-versus-host disease, increasing susceptibility to opportunistic infections.

Benefit determinationActual coverage and extent of services are determined by the member's plan benefit terms and medical necessity criteria.

Clinical implicationPatients require monitoring and management for infection risk and other complications related to immunosuppression and conditioning regimens.

Policy Summary

PayerCapital Bluecross

PolicyPlacental/umbilical cord blood as a source of stem cells

Policy CodePolicy MP 9.001

Change TypeAdministrative update — no material clinical changes

Effective DateDec 1, 2025

Next Review Date

Key ActionObtain prior authorization when billing the listed cord blood procedure codes (S2140, S2142, S2150).

SourceLink

On This Page

OpenPayer

Placental/umbilical cord blood as a source of stem cells

Coverage Criteria — Placental / Umbilical Cord Blood

Procedure and Billing Codes

Provider Actions, Authorization, and Documentation

Candidate Criteria for Allogeneic Transplantation

Evaluation and Clinical Context Requirements

Center and Facility Requirements

Background — Hematopoietic Cell Transplantation

Definitions

Post-Transplant Coverage Considerations

S2140	Umbilical cord blood — processing/handling (as listed)
S2142	Umbilical cord blood — collection (as listed)
S2150	Umbilical cord blood — storage (as listed)